Inflammatory Bowel Disease

There are currently many new and emerging therapies treating inflammatory bowel disease.

There are many different treatments for inflammatory bowel disease, and choosing the right one for a patient with a new diagnosis can be a challenge.

The FDA has approved Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. This was the top story in gastroenterology last week.

Time to patient presentation was the largest component of time to diagnosis of inflammatory bowel disease, according to research published in Alimentary Pharmacology & Therapeutics.

Last week’s top story in gastroenterology was about the state of racial injustice in America and how the medical community should be responding to it.

For patients with inflammatory bowel disease, telehealth was cost-saving and had high probability of cost-effectiveness, according to results published in Clinical Gastroenterology and Hepatology.

Patients with Crohn’s disease or ulcerative colitis who underwent PCI had a lower rate of in-hospital MACCE, mortality and stroke or transient ischemic attack compared with those without inflammatory bowel disease, researchers reported.

The COVID-19 crisis has totally changed the way we think about telehealth. The perceived barriers to virtual care before the pandemic have largely disappeared. Everywhere around the country doctors and advanced practice providers are ramping up phone or video visits, and it seems that most patients are grateful to be able to connect with their provider in a safe manner.

COVID-19 has accelerated the need for GI practices to use telehealth as a way to deliver patient care and has forced GI practices to rapidly transition to telehealth.

Patients with inflammatory bowel disease were at greater risk for developing dementia, according to research published in Gut.